PAH Deficiency is a PRIMARY Genetic Disease, Not Secondary
Phenylalanine hydroxylase (PAH) deficiency is definitively a primary disease—it is an autosomal recessive genetic disorder caused by biallelic pathogenic variants in the PAH gene, not a consequence of another condition 1, 2.
Disease Classification
PAH deficiency (which encompasses phenylketonuria [PKU] and hyperphenylalaninemia [HPA]) is classified as:
- A primary inborn error of metabolism caused by deficient activity of hepatic phenylalanine hydroxylase enzyme 2
- An autosomal recessive inherited disorder resulting from mutations in the PAH gene 3, 4
- OMIM 261600 - catalogued as a distinct genetic entity 2
The disease is caused by deficient PAH enzyme activity (EC1.14.16.1), which normally converts phenylalanine to tyrosine with its cofactor tetrahydrobiopterin (BH4). This enzymatic deficiency is the primary pathology, not a secondary manifestation of another disease process 2.
Important Distinction
The guidelines explicitly note that while elevated phenylalanine levels can also occur in patients with defects in BH4 synthesis or recycling, these conditions are distinct from PAH deficiency and represent different primary disorders 2. This clarification underscores that PAH deficiency itself is the primary pathogenic entity.
Clinical Implications
- Genetic testing for PAH variants is recommended at birth to confirm diagnosis 1
- The disease requires lifelong management with phenylalanine restriction to prevent intellectual disability and other complications 1, 2
- Newborn screening identifies affected individuals presymptomatically, allowing early treatment of this primary genetic disorder 1, 2